血友病患者骨骼肌肉病变的手术治疗策略与凝血因子消耗
回顾性分析261例血友病患者共338例次骨科手术,大型手术占79.9%,关节置换占60.1%。术前FⅧ平均用量44.4±8.1 IU/kg,术后2周平均647±177 IU/kg。单次麻醉下多关节手术不增加凝血因子消耗,更具成本效益。
要点
- 血友病骨骼肌肉病变在合理凝血因子替代下手术有效。
- 大型手术占79.9%,关节置换占60.1%。
- 单次麻醉多关节手术不增加凝血因子消耗,成本效益更佳。
核心结论
- 在合理补充凝血因子条件下,根据病变具体情况选择合适手术方案可有效缓解血友病性骨骼肌肉病变症状。
- 单次麻醉下行多关节手术不增加凝血因子消耗,较分期单关节手术更具成本效益。
研究设计与样本
- 回顾性分析1996年1月至2019年12月北京协和医院骨科因骨骼肌肉病变接受手术的261例血友病患者,共338例次手术。
- 根据手术创伤大小选择凝血因子替代治疗方案,记录临床表现、手术种类、围手术期凝血因子消耗、输血率及再手术情况。
- 对比单次麻醉下单部位手术与多部位手术的凝血因子消耗及费用。
主要发现
- 338例次手术中大型手术270例次(79.9%),关节置换203例次(60.1%)。
- 因手术部位病变复发再手术14例,再致残率4.2%;55例(21.1%)围手术期接受红细胞输注。
- 血友病A患者术前FⅧ平均用量44.4±8.1 IU/kg,术后2周内FⅧ总用量平均647±177 IU/kg(40 962 IU)。
- 术后3个月康复期内6例(2.3%)发生手术部位再出血;7例术后检出FⅧ抑制物,平均13.7±11.2 BU/ml。
- 单次麻醉下多关节手术组(68例)与单关节手术组凝血因子消耗量及费用差异无统计学意义。
关键数值与推荐
- 血友病A患者术前FⅧ平均用量44.4±8.1 IU/kg,术后2周内FⅧ总用量平均647±177 IU/kg(40 962 IU)。
- 术后检出FⅧ抑制物7例,平均抑制物水平13.7±11.2 BU/ml。
临床怎么用
- 对血友病性关节病及骨骼肌肉病变,在合理凝血因子替代下可选择手术治疗。
- 对适合患者,可考虑单次麻醉下行多关节手术,不增加凝血因子消耗且成本效益更佳。
局限性
- 本文为单中心回顾性研究,证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study the orthopedic treatment strategy for hemophilia complicated with musculoskeletal disorders as well as the peri-operative consumption of clotting factor. Methods: Total 338 orthopedic surgeries were performed for 261 patients, average age of 30.6 y (6-65 y) , with hemophilia between January 1996 and December 2019 at our institute. Two hundred and twenty-six patients presented with bleeds within the joints. Sixty-one patients presented with intramuscular bleeds, 45 presented with hemophilic pseudotumors, and six presented with miscellaneous complaints. Strategy of clotting factor replacement therapy was designed as per differences in the level of the operation procedure. Information regarding clinical manifestation, operative strategy, clotting factor consumption, and re-operation for complications was retrospectively recorded. The costs for multiple joint procedure and single joint procedure were studied. Results: We found that 270 of the 338 surgical procedures were major surgical procedures (79.9%) . There were 203 procedures of joint arthroplasty (60%) . Fourteen patients underwent reoperations for local recurrence (4.2%) . The average factor Ⅷ consumption before the surgery was 44.4 ± 8.1 IU/kg. The average FⅧ consumption within postoperative 2 weeks was 40 962 IU (647±177 IU/kg) . Seven type A hemophilic patients developed F Ⅷ inhibitor following the surgical procedure, with an average level of 13.7±11.2 BU/mL. Sixty-eight patients underwent multiple joint procedures under one anesthesia session (26%) . There was no significant difference in the factor consumption between the multiple joint procedure and single joint procedure. Conclusions: Surgical treatment was found to be effective for hemophilic arthropathy and lesion of the musculoskeletal apparatus, with the clotting factor replacement therapy. Multiple joint procedures under one anesthesia were more cost effective for patients with hemophilia, with less factor consumption than staged single joint procedure. 目的: 探讨血友病性骨骼肌肉病变的外科手术治疗方法及围手术期凝血因子消耗情况。 方法: 回顾性分析1996年1月至2019年12月在中国医学科学院北京协和医院骨科因骨骼肌肉病变接受手术治疗的261例血友病患者。根据手术创伤大小选择凝血因子替代治疗方案。记录病变的临床表现、手术种类、围手术期凝血因子消耗、输血率及再手术情况,对比单次麻醉下单部位手术与多部位手术的凝血因子消耗及费用。 结果: 261例患者均为男性,平均年龄为30.6(6~65)岁。血友病A 235例,血友病B 26例;重型(因子活性<1%)141例,中间型(因子活性1%~5%)91例,轻型(因子活性>5%)29例。共施行手术338例次(关节内出血及关节炎226例次、血友病并发肌腱肌膜出血挛缩61例次、血友病假瘤45例次、其他6例次)。338例手术中,大型手术270例(79.9%),关节置换203例(60.1%)。因手术部位病变复发再手术14例,再致残率为4.2%。共55例(21.1%)患者在围手术期接受红细胞输注。血友病A患者术前FⅧ的平均用量为(44.4±8.1)IU/kg,术后2周内FⅧ总用量平均为(647±177)IU/kg(40 962 IU)。术后3个月康复期内,6例(2.3%)患者发生手术部位再出血。7例患者术后检出FⅧ抑制物,平均抑制物水平为(13.7±11.2)BU/ml。单次麻醉下多关节手术组(68例)与单关节手术组凝血因子消耗量及费用差异无统计学意义。 结论: 针对血友病性骨骼肌肉病变,在合理补充凝血因子条件下,根据病变的具体情况选择合适的手术治疗方案是有效的缓解症状的方法。单次麻醉及凝血因子替代治疗下进行多关节手术不增加凝血因子消耗,具有更佳的成本效益。.
引用
- Feng B, Zhu W, Gao P, et al. [Orthopedic treatment of musculoskeletal disorders in hemophilic patients]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33333692. doi:10.3760/cma.j.issn.0253-2727.2020.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。